Tuberculosis
Drug research and approvals for tuberculosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 17, 2026, 154 studies of tuberculosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 6 drug trials for it since 2013, FDA has 8 approved and 22 open orphan designations naming it, and the EU has 4 authorised medicines for it.
- Recruiting worldwide: 154
- Trials authorized in Canada: 6
- FDA orphan approvals: 8
- EU medicines: 4
Recruiting Now
Newest start dates first, of 154 recruiting on ClinicalTrials.gov ↗- A Phase 1 Multiple Dose Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, Drug-Drug…NCT07883226 · Phase 1 · Gates Medical Research Institute · starts Oct 21, 2026
- Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active…NCT07163143 · Phase 3 · University College, London · starts Oct 12, 2026
- A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years…NCT07124559 · Phase 1 / Phase 2 · National Institute of Allergy and Infectious Diseases (NIAID) · starts Sep 28, 2026
- Clinical Characteristics, Treatment, Diagnostic Findings, and Outcomes of Tuberculous Meningitis in Indonesia, 2022-2025NCT07929519 · Not reported · Ina-Respond · starts Sep 24, 2026
- Fibroblast Activating Protein (FAP) PET/CT in Adults With TuberculosisNCT07830771 · Early Phase 1 · University of Pennsylvania · starts Sep 22, 2026
- Effectiveness of Chat-based Mobile Application for Consultation (Zalo) in Improving Compliance With Follow-up Tests…NCT07234929 · Not applicable · Gia Dinh People Hospital · starts Sep 15, 2026
- rBCG-N-RSV Vaccine in Adults Aged 60 Years and OlderNCT07762014 · Phase 2 · Biothervax SpA · starts Sep 14, 2026
- Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in…NCT07486024 · Phase 3 · Assistance Publique - Hôpitaux de Paris · starts Sep 11, 2026
- A Phase I Study of Lipovaxin Tuberculosis Vaccine in Adult Healthy PopulationsNCT07647107 · Phase 1 · PT Bio Farma · starts Sep 8, 2026
- Bronchial Artery Embolization and Bronchoscopy in The Management of Hemoptysis in Cavitary Tuberculosis Lung LesionsNCT07940413 · Not applicable · Al-Azhar University · starts Sep 1, 2026
Drug Pipeline
16 approved, 31 in phase 3, 34 in phase 2, 16 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Isoniazid, Rifampin, Pyrazinamide, Rifapentine, Ethambutol, Bedaquiline, Delamanid, Pretomanid, Rifabutin, Protionamide, Cycloserine, Capreomycin, Streptomycin, Ethionamide, Aminosalicylic acid, Rifamycin
- Moxifloxacin
- Phase 3 Topoisomerase IV inhibitor
- Bcg vaccine
- Phase 3
- Levofloxacin anhydrous
- Phase 3 DNA gyrase inhibitor
- Linezolid
- Phase 3 Bacterial 70S ribosome inhibitor
- Clofazimine
- Phase 3 DNA inhibitor
- Cholecalciferol
- Phase 3 Vitamin D receptor agonist
- Efavirenz
- Phase 3 Human immunodeficiency virus type 1 reverse transcriptase inhibitor
- Pyridoxine
- Phase 3 Supplement
- Doxycycline anhydrous
- Phase 3 Matrix metalloproteinase 7 inhibitor
- Lamivudine
- Phase 3 Human immunodeficiency virus type 1 reverse transcriptase inhibitor
- Nevirapine
- Phase 3 Human immunodeficiency virus type 1 reverse transcriptase inhibitor
- Gatifloxacin
- Phase 3 DNA gyrase inhibitor
- Kanamycin
- Phase 3 Bacterial 70S ribosome inhibitor
- Tuberculin
- Phase 3
- Abacavir
- Phase 3 Human immunodeficiency virus type 1 reverse transcriptase inhibitor
- Didanosine
- Phase 3 Human immunodeficiency virus type 1 reverse transcriptase inhibitor
- Meloxicam
- Phase 3 Cyclooxygenase-2 inhibitor
- Zidovudine
- Phase 3 Human immunodeficiency virus type 1 reverse transcriptase inhibitor
- Ergocalciferol
- Phase 3 Vitamin D receptor agonist
- Prednisone
- Phase 3 Glucocorticoid receptor agonist
- Sulfamethoxazole
- Phase 3 Bacterial dihydropteroate synthase inhibitor
- Trimethoprim
- Phase 3 Bacterial dihydrofolate reductase inhibitor
- Clarithromycin
- Phase 3 Bacterial 70S ribosome inhibitor
- Sitafloxacin anhydrous
- Phase 3 Bacterial DNA gyrase inhibitor
- Retinol
- Phase 3
- Folic acid
- Phase 3
- Niacin
- Phase 3
- Lactose, anhydrous
- Phase 3
- Zinc ion
- Phase 3
- Sudapyridine
- Phase 3
Showing the 30 furthest along of 81 in trials.
How Its Trials Ended
1,403 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 319 whose ending is known, 61% met their primary endpoint, 14% missed it and 25% stopped early.
- Completed, result not reported59642%
- Ongoing27420%
- Status unknown21415%
- Met its primary endpoint19314%
- Stopped: other or unclear504%
- Missed its primary endpoint463%
- Stopped: enrollment or feasibility171%
- Stopped: lack of efficacy60%
- Stopped: sponsor or business decision30%
- Stopped: safety20%
- Stopped: funding20%
Trials Authorized in Canada
Newest first; search them all in Canada trials| Feb 27, 2026 | Assessment of safety and accuracy of cy-tb, a newtuberculosis-specific skin testCy-tb/siiltibcy (RDESAT-6/RCFP-10) | Research Institute Of The Mcgill University Health Centre | Pending |
| Oct 31, 2024 | Study 38 - phase 2c clinical trial of novel, short-course regimens for the treatment of pulmonary tuberculosis: crush-tb (combination regimens for shortening…bedaquiline/ delamanid/ moxifloxacin/ rifabutin | Research Institute Of The Mcgill University Health Centre | Ongoing |
| Oct 8, 2024 | Sstarlet: shorter and safer treatment regimens for latent tbRifapentine / levofloxacin / rifampin / bedaquiline | Research Institute Of The Mcgill University Health Centre | Ongoing |
| Aug 10, 2021 | Six weeks of daily rifapentine vs. a comparator arm of 12-16 week rifamycin-based treatment of latent m. tuberculosis infection: assessment of safety,…Rifapentine | Research Institute Of The Mcgill University Health Centre | Ongoing |
| Jul 4, 2019 | 2r2: higher dose rifampin for 2 months vs standard dose rifampin for latent tb:a 3-arm randomized trialRifampin | Research Institute Of The Mcgill University Health Centre | Ongoing |
| Jan 21, 2016 | Taima tb 3hp study: acceptability and completion rates of a new 12 dose treatment (3 month) compared to the standard treatment for latent tb infection treatmentRifapentine | Ottawa Hospital Research Institute | Closed |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 30| Jul 28, 2025 | SirturoAs part of combination therapy in the treatment of adult and pediatric patients (2 years and older and weighing at least 8 kg) with… | Janssen Research & Development, LLC | Approved |
| May 27, 2020 | SirturoSIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adult and pediatric patients (5 years and… | Janssen Research & Development, LLC | Approved |
| Aug 14, 2019 | PretomanidPretomanid tablet is indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary… | Global Alliance for TB Drug Development | Approved |
| Aug 9, 2019 | SirturoSIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adult and pediatric… | Janssen Research & Development, LLC | Approved |
| Dec 28, 2012 | SirturoPart of combination therapy in adults (greater than or equal to 18 years) with pulmonary multi-drug resistant tuberculosis (MDR-TB). | Janssen Research & Development, LLC | Approved |
| Jun 22, 1998 | PriftinTreatment of pulmonary tuberculosis. | Hoechst Marion Roussel | Approved |
| Jun 30, 1994 | Paser GranulesTreatment of tuberculosis | Jacobus Pharmaceutical Company | Approved |
| May 31, 1994 | RifaterShort-course treatment of tuberculosis. | Hoechst Marion Roussel | Approved |
| Jan 26, 2026 | SorfequilineTreatment of tuberculosis | TB Alliance | Designated |
| Apr 14, 2025 | SudapyridineTreatment of tuberculosis | Shanghai Jiatan Pharmatech Co., Ltd | Designated |
| Nov 6, 2023 | Alpibectir and ethionamide fixed-dose combination drugTreatment of tuberculosis | Bioversys SAS | Designated |
| Dec 1, 2020 | 5-{[(5-amino-3,3-dihydroxyoxolan-2-yl)oxy][5-(2,4-dioxo-1,2,…Treatment of Tuberculosis | PAI Life Sciences Inc. | Designated |
| Dec 23, 2019 | Mycobacterium vaccaeTreatment of Tuberculosis | Immunitor Inc. | Designated |
| Mar 15, 2018 | 2-[(2S)-2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]-8-nitro-…Treatment of Tuberculosis (TB) | LMU Klinikum AöR | Designated |
| Sep 26, 2017 | Nitric oxideTreatment of non-tuberculosis mycobacterial (NTM) infections | Advanced Inhalation Therapies Ltd. | Designated |
Medicines Authorised in the EU
Newest first| Jan 13, 2025 | SiiltibcyMycobacterium tuberculosis derived antigens (rdESAT-6 / rCFP-10) | Serum Life Science Europe GmbH | EMA ↗ |
| Jul 31, 2020 | Dovprela (previously Pretomanid FGK)Pretomanid · orphan | Viatris Healthcare Limited | EMA ↗ |
| Apr 27, 2014 | DeltybaDelamanid | Otsuka Novel Products GmbH | EMA ↗ |
| Mar 5, 2014 | SirturoBedaquiline | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA